Partners and Investors
Partnership Collaboration and Investment Opportunities
Cend will enter partnerships to enable more effective solid tumor cancer delivery for a range of therapeutic modalities.
Cend and its collaborators have demonstrated ability to enhance delivery and antitumor activity of:
- Antibodies, including checkpoint inhibitors
- Antibody-drug conjugates (ADCs)
- Adoptive cell immunotherapies, such as
CAR-T
Natural killer (NK) cell therapies
Cytotoxic T lymphocytes (CTLs)
- Cytokines, such as IL-2 and IL-15
- Nucleic acid-based drugs
Antisense
siRNA
microRNA
messenger RNA (mRNA)
Immunostimulatory oligonucleotides
CRISPR
